{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:49:03Z","timestamp":1792655343303,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T00:00:00Z","timestamp":1462579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gittlen Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.gendis.2016.04.007","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T21:15:38Z","timestamp":1463001338000},"page":"198-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1059,"title":["Temozolomide resistance in glioblastoma multiforme"],"prefix":"10.1016","volume":"3","author":[{"given":"Sang Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2016.04.007_bib1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/ph7070797","article-title":"The medicinal chemistry of imidazotetrazine prodrugs","volume":"7","author":"Moody","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.gendis.2016.04.007_bib2","first-page":"2393","article-title":"Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer","volume":"3","author":"Reid","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.12-9-1114","article-title":"Temozolomide for the treatment of metastatic melanoma: a systematic review","volume":"12","author":"Quirt","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2016.04.007_bib5","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib6","first-page":"CD007415","article-title":"Temozolomide for high grade glioma","volume":"4","author":"Hart","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gendis.2016.04.007_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib8","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1158\/1078-0432.CCR-05-0722","article-title":"Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme","volume":"11","author":"Cohen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib9","doi-asserted-by":"crossref","first-page":"11499","DOI":"10.1158\/0008-5472.CAN-07-5312","article-title":"Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter","volume":"67","author":"Alonso","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/bjc.1993.241","article-title":"Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells","volume":"67","author":"Baer","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib11","first-page":"2725","article-title":"Multifaceted resistance of gliomas to temozolomide","volume":"8","author":"Bocangel","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3171\/jns.2003.99.6.1047","article-title":"Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide","volume":"99","author":"Kanzawa","year":"2003","journal-title":"J Neurosurg"},{"key":"10.1016\/j.gendis.2016.04.007_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/sj.bjc.6601193","article-title":"Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide","volume":"89","author":"Kanzawa","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib14","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-05-0036","article-title":"IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide","volume":"65","author":"Natsume","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-5-67","article-title":"Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma","volume":"5","author":"Liu","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2005.03583.x","article-title":"O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells","volume":"96","author":"Hermisson","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.gendis.2016.04.007_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3171\/jns.2007.106.4.646","article-title":"Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells","volume":"106","author":"Uzzaman","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1016\/j.gendis.2016.04.007_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-007-0520-x","article-title":"A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation","volume":"61","author":"Natsume","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.gendis.2016.04.007_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.canlet.2010.04.013","article-title":"miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells","volume":"296","author":"Ujifuku","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2016.04.007_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6605712","article-title":"Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide","volume":"103","author":"van Nifterik","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib21","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/0008-5472.CAN-10-3213","article-title":"Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair","volume":"71","author":"Goellner","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib22","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/ijc.25888","article-title":"HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A","volume":"129","author":"Lee","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI59334","article-title":"Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients","volume":"122","author":"Agnihotri","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2016.04.007_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.gendis.2016.04.007_bib25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1471-4159.2012.07781.x","article-title":"Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells","volume":"122","author":"Happold","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.gendis.2016.04.007_bib26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","article-title":"STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression","volume":"11","author":"Kohsaka","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2016.04.007_bib27","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1038\/mtna.2013.60","article-title":"Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity","volume":"2","author":"Munoz","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.gendis.2016.04.007_bib28","doi-asserted-by":"crossref","first-page":"e1145","DOI":"10.1038\/cddis.2014.111","article-title":"Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43","volume":"5","author":"Munoz","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2016.04.007_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-015-1899-6","article-title":"Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics","volume":"125","author":"St-Coeur","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mrgentox.2015.06.001","article-title":"APE1\/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line","volume":"793","author":"Montaldi","year":"2015","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"10.1016\/j.gendis.2016.04.007_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12885-015-1191-3","article-title":"Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status","volume":"15","author":"Chong","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gendis.2016.04.007_bib32","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1590\/S1807-59322011001000013","article-title":"Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma","volume":"66","author":"Uno","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.gendis.2016.04.007_bib33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2016.04.007_bib34","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-010-0283-9","article-title":"Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma","volume":"102","author":"Blough","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/sj.onc.1207244","article-title":"p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition","volume":"23","author":"Wang","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.gendis.2016.04.007_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","article-title":"Antitumor activity of NVP-BKM120\u2013a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells","volume":"18","author":"Koul","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib38","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/1078-0432.CCR-13-1856","article-title":"Novel MSH6 mutations in treatment-na\u00efve glioblastoma and anaplastic oligodendroglioma contribute totemozolomide resistance independently of MGMT promoter methylation","volume":"20","author":"Nguyen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib39","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0006-2952(02)00876-6","article-title":"Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance","volume":"63","author":"Ma","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.gendis.2016.04.007_bib40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.2005.02.9405","article-title":"Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas","volume":"24","author":"Bredel","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib41","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1158\/1535-7163.MCT-05-0428","article-title":"Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line","volume":"5","author":"Auger","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2016.04.007_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000306139","article-title":"Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications","volume":"78","author":"Zhang","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.gendis.2016.04.007_bib43","doi-asserted-by":"crossref","first-page":"39759","DOI":"10.1074\/jbc.M110.147504","article-title":"Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain","volume":"285","author":"Oliva","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2016.04.007_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/ol.2010.210","article-title":"Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells","volume":"2","author":"Lee","year":"2011","journal-title":"Oncol Lett"},{"key":"10.1016\/j.gendis.2016.04.007_bib45","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbrc.2015.10.122","article-title":"Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis","volume":"468","author":"Ueno","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.gendis.2016.04.007_bib46","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3892\/ol.2015.3130","article-title":"NF-\u03baB inhibitor reverses temozolomide resistance in human glioma TR\/U251 cells","volume":"9","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.gendis.2016.04.007_bib47","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-14-3616","article-title":"Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide","volume":"75","author":"McFaline-Figueroa","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2016.04.007_bib48","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1080\/15384101.2015.1090063","article-title":"The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma","volume":"14","author":"Banelli","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gendis.2016.04.007_bib49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1215\/S1152851704000821","article-title":"Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme","volume":"7","author":"Giannini","year":"2005","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1535-7163.MCT-08-0854","article-title":"Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines","volume":"8","author":"Clarke","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2016.04.007_bib51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1215\/15228517-2008-090","article-title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts","volume":"11","author":"Kitange","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11060-014-1635-7","article-title":"Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme","volume":"121","author":"Hunn","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib53","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2016.04.007_bib54","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11060-009-9976-3","article-title":"Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide","volume":"96","author":"Dresemann","year":"2010","journal-title":"J Neurooncol"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304216300162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304216300162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T11:04:30Z","timestamp":1567854270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304216300162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S2352304216300162"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide resistance in glioblastoma multiforme","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}